Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of drugmaker Elan
So what: In 2009, Elan sold the rights to its Alzheimer's' immunotherapy program to Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson
Now what: Bad news all around today, because there aren't many options available to treat Alzheimer's. Eli Lilly
Speaking specifically of Elan, which is best known for multiple sclerosis drug Tysabri, which it markets in partnership with Biogen Idec
Craving more input? Start by adding Elan to your free and personalized Watchlist so you can keep up on the latest news with the company.